Risankizumab - AbbVie/Boehringer Ingelheim
Alternative Names: ABBV 066; BI-655066; risankizumab-rzaa; SKYRIZILatest Information Update: 30 Aug 2024
At a glance
- Originator Boehringer Ingelheim
- Developer AbbVie; Boehringer Ingelheim
- Class Anti-inflammatories; Antiasthmatics; Antipsoriatics; Antirheumatics; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Interleukin-23 subunit p19 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Crohn's disease; Plaque psoriasis; Psoriasis; Psoriatic arthritis
- Registered Erythrodermic psoriasis; Generalised pustular psoriasis; Ulcerative colitis
- Phase III Palmoplantar pustulosis
- Phase II Atopic dermatitis; Hidradenitis suppurativa
- No development reported Unspecified
- Discontinued Ankylosing spondylitis; Asthma
Most Recent Events
- 26 Aug 2024 AbbVie plans a phase I pharmacokinetics trial for Healthy volunteers in September 2024 (SC, Injection) (NCT06571266)
- 26 Jul 2024 Registered for Ulcerative colitis (In adolescents, In the elderly, In adults) in Norway, Norway, Liechtenstein, Iceland, European Union (IV)
- 23 Jul 2024 Abbvie initiates enrolment in a phase I pharmacokinetics trial(In volunteers) in USA (IV)(SC) (NCT06487572)